Myocardial Infarction Size Reduction With Atorvastatin
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||Prevention of Reperfusion Damage and Late Left Ventricular Remodelling With Atorvastatin Administered Before Reperfusion Therapy. The REPERATOR Study|
- Left ventricular end systolic volume index as measured by cine magnetic resonance imaging (MRI) at 3 month follow-up
- Other MRI measurements of global and regional left ventricular function
- MRI measurements of infarct size at admission, 1 week, and 3 months, as well as changes in these measures between MRI investigations
- Biochemical markers of infarct size
- Blush grade
|Study Start Date:||February 2006|
|Study Completion Date:||February 2008|
|Primary Completion Date:||February 2008 (Final data collection date for primary outcome measure)|
Left ventricular remodelling after a myocardial infarction refers to changes in shape and function of the infarcted and uninfarcted myocardium. Remodelling begins minutes after acute myocardial infarction and may continue for months or years, leading to dilation of the left ventricle (LV) and an increased LV volume. As studies show, LV volume strongly correlates with long-term mortality. Reperfusion after a period of ischaemia (through medication or PTCA) leads to so-called 'reperfusion injury'. This results in myocardial dysfunction and damage, which can lead to LV remodelling.
In a study where atorvastatin was administered at the onset of reperfusion infarct size was reduced. Atorvastatin led to protection of the reperfused myocardium, independently of its effects on cholesterol.
The objective is to measure the effect of atorvastatin, administered orally before reperfusion therapy by PTCA, on infarct size and microvascular reperfusion.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00286312
|St. Antonius Hospital|
|Nieuwegein, Netherlands, 3435CM|
|University Medical Centre Utrecht|
|Principal Investigator:||Benno Rensing, MD, PhD||St. Antonius Ziekenhuis Nieuwegein|